Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Involvement of pharmacies in tuberculosis treatment

Ana Antunes, Joana Gomes, Inês Belchior, Ana Isabel Loureiro, Aurora Carvalho, Anabela Madeira, Raquel Duarte
European Respiratory Journal 2012 40: 1581-1582; DOI: 10.1183/09031936.00005012
Ana Antunes
*Centro Hospitalar Vila Nova de Gaia/Espinho, EPE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ana.oliveirinha2@gmail.com
Joana Gomes
*Centro Hospitalar Vila Nova de Gaia/Espinho, EPE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inês Belchior
#Hospital Sao Joao, EPE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Isabel Loureiro
¶Centro Hospitalar Trás-os-Montes e Alto Douro, Vila Real
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aurora Carvalho
*Centro Hospitalar Vila Nova de Gaia/Espinho, EPE
+CDP de Vila Nova de Gaia, Vila Nova de Gaia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anabela Madeira
§Associação Nacional de Farmácias, Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raquel Duarte
*Centro Hospitalar Vila Nova de Gaia/Espinho, EPE
+CDP de Vila Nova de Gaia, Vila Nova de Gaia
fCentro de Referência Regional do Norte de Tuberculose Multirresistente
**Faculdade de Medicina da Universidade do Porto, Porto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editors:

In a recent issue of the European Respiratory Journal, Yew et al. [1] recalled the change from DOTS (directly observed treatment, short course) strategy to a more comprehensive approach, the Stop TB Strategy, adopted by the World Health Organization. Three of the six components of this strategy are the pursuit of high-quality DOTS expansion and enhancement, the engagement of all care providers, and the empowerment of people with tuberculosis and communities through partnership. We present a project based on the decentralisation of treatment and on patient participation in the choice of DOT supporter, in line with the Stop TB Strategy as presented by Yew et al. [1]. In Portugal, DOT is mandatory, and is performed principally in an outpatient setting within Pulmonary Health Centers (CDPs); these are primary care units dedicated to the diagnosis, treatment and surveillance of tuberculosis. Tuberculosis patients continue to suffer from social stigma and find it embarrassing to be subjected to DOT in CDP facilities. To deal with this problem, the Vila Nova de Gaia CDP team and the National Association of Pharmacies (ANF) designed and implemented a 6-month pilot programme permitting DOT in community pharmacies of the county of Vila Nova de Gaia. The aim was to assess the feasibility of such an innovation and its effect on patient outcomes.

The CDP medical team defined the inclusion criteria: all new cases of fully drug-susceptible tuberculosis [2] in the continuation phase of treatment and expressing displeasure at being forced to receive treatment at the CDP were eligible. The ANF conducted a survey of pharmacies in Vila Nova de Gaia county to identify those with the physical infrastructure, the staff capacity and the willingness to participate in the programme. No reward was offered, the gain to the pharmacies being a strengthened relationship with patients from a community with possible commercial benefits. The pharmacists were trained by CDP doctors. Training included a discussion of tuberculosis epidemiology, the immunopathogenesis of Mycobacterium tuberculosis, and tuberculosis diagnosis and treatment. Within this overall theme, the concept of DOT and the rules for effective DOT were defined. An administration guidebook was prepared. This functioned simultaneously to assist in anti-tuberculosis drug prescription as well as to provide indicators of compliance with therapy. Selected patients were invited to participate in DOT at a pharmacy near their homes. No patient was obliged to accept the treatment transfer. After patient agreement was secured, the local pharmacist was contacted to determine the day on which DOT would commence. The drug administration guidebook and the anti-tuberculosis drugs were delivered to the pharmacy 2 days prior to the first local DOT. Telephone contact was established between each pharmacy and each patient’s physician to ensure rapid resolution of any problematic situations, including treatment fault. In such an instance, it was agreed that the patient would be summoned to the CDP. Monthly meetings were conducted between the CDP team, the ANF delegate and participating pharmacists to monitor the situation of all patients and to evaluate programme success. All participating patients were asked to complete a questionnaire assessing their satisfaction at day 30 and at the end of the treatment. Patients continued to receive monthly consultations with their CDP doctors. To assess programme success, the outcomes of all patients were noted and compared with those of outpatients undergoing DOT in CDPs nationwide.

12 local pharmacies joined the programme. From June to December 2009, the programme was offered to 14 patients who fulfilled the inclusion criteria. There were eight males and six females, all new cases and none of them were immigrants or HIV positive. All of them had completed 2 months of an isoniazid (H), rifampicin (R), pyrazinamide and ethambutol regimen at the CDP (achieving negative smear and culture), and were initiating 4 months of HR at the time of transfer. The responses to the questionnaires completed on day 30 and at the end of treatment revealed high levels of satisfaction from all patients. During the 6 months of the programme, no anomalous situation with respect to DOT was observed and no faults in the treatment occurred. The operation of the pharmacies continued as normal. All patients fully completed treatment with 100% cure [2]. No tuberculosis relapse was noted upon follow-up of the 14 patients.

In 2009, the cure rate of tuberculosis patients receiving DOT in CDPs nationwide was 87% [3]. Our cure rate was 100%. In terms of sample size, the probability of such an outcome was only 14.23% (0.8714=0.1423) if it is assumed that the probability that our patients would receive effective treatment was the same as that of tuberculosis patients treated at CDPs. Despite our small sample size, the result suggests an improvement in the treatment outcome’s prospects with our model.

The use of a facility other than a CDP by tuberculosis patients embarrassed by the social stigma associated with everyday visits to a “known tuberculosis centre” promotes adherence by tailoring DOT to the patient needs.

The limitations of our study are that we compared our results with nationwide data and did not randomise study groups. However, as we sought to develop an alternative DOT model to assist patients at risk of nonadherence because of embarrassment associated with visiting the CDP facility, we considered it unethical to randomise disaffected patients; this would have increased the risk of nonadherence in patients assigned to continue CDP-based DOT.

Thus, we formed a public–private partnership to develop a DOT programme serving patient needs, and observed 100% adherence and cure. These results confirm earlier findings on the utility of the participation of pharmacies in TB treatment [4] in agreement with the principles of the new European Union Standards for Tuberculosis Care [5].

Footnotes

  • Statement of Interest

    None declared.

  • ©ERS 2012

REFERENCES

  1. ↵
    1. Yew WW,
    2. Lange C,
    3. Leung CC
    . Treatment of tuberculosis: update 2010. Eur Respir J 2011; 37: 441–462.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    World Health Organization. Treatment of tuberculosis – guidelines for national programmes, 4th Edn. Geneva, World Health Organization, 2009.
  3. ↵
    ARS Norte. Congresso Internacional de Cuidados Paliativos. [International Congress on Palliative Care.] www.arsnorte.min-saude.pt/portal/page/portal/ARSNorte Date last accessed: April 30, 2011.
  4. ↵
    1. Juan G,
    2. Lloret T,
    3. Perez C,
    4. et al
    . Directly observed treatment for tuberculosis in pharmacies compared with self-administered therapy in Spain. Int J Tuberc Lung Dis 2006; 10: 215–221.
    OpenUrlPubMed
  5. ↵
    1. Migliori GB,
    2. Zellweger JP,
    3. Abubakar I,
    4. et al
    . European Union Standards for Tuberculosis Care. Eur Respir J 2012; 39: 807–819.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 40 Issue 6 Table of Contents
European Respiratory Journal: 40 (6)
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Involvement of pharmacies in tuberculosis treatment
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Involvement of pharmacies in tuberculosis treatment
Ana Antunes, Joana Gomes, Inês Belchior, Ana Isabel Loureiro, Aurora Carvalho, Anabela Madeira, Raquel Duarte
European Respiratory Journal Dec 2012, 40 (6) 1581-1582; DOI: 10.1183/09031936.00005012

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Involvement of pharmacies in tuberculosis treatment
Ana Antunes, Joana Gomes, Inês Belchior, Ana Isabel Loureiro, Aurora Carvalho, Anabela Madeira, Raquel Duarte
European Respiratory Journal Dec 2012, 40 (6) 1581-1582; DOI: 10.1183/09031936.00005012
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • GOLD 2023 taxonomy: new tool to determine COPD etiotypes
  • Latent COPD: a proposed new term in the disease nomenclature
  • Empiric anti-anaerobic antibiotics are associated with adverse clinical outcomes
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society